Hutchmed
Hutchmed, officially known as Hutchison China MediTech Limited, is a prominent biopharmaceutical company headquartered in Hong Kong. Founded in 2016, Hutchmed has rapidly established itself as a leader in the oncology and immunology sectors, focusing on the discovery, development, and commercialisation of innovative therapies. With a strong operational presence in China and the United States, Hutchmed has achieved significant milestones, including the successful launch of its flagship products, which are designed to address unmet medical needs in cancer treatment. The company’s unique approach combines cutting-edge research with a deep understanding of local markets, positioning it favourably within the competitive biopharmaceutical landscape. Hutchmed's commitment to advancing healthcare solutions has garnered recognition, making it a notable player in the global biopharmaceutical industry.
DitchCarbon Score
How does Hutchmed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hutchmed's score of 22 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hutchmed's reported carbon emissions
In 2023, Hutchmed reported total carbon emissions of approximately 78,772,000 kg CO2e. This figure includes 320,000 kg CO2e from Scope 1 emissions, 6,640,000 kg CO2e from Scope 2 emissions, and a significant 71,812,000 kg CO2e from Scope 3 emissions, which encompasses various categories such as purchased goods and services, employee commute, and business travel. In 2022, the company’s total emissions were about 5,933,000 kg CO2e, with Scope 1 emissions at 244,000 kg CO2e and Scope 2 emissions at 6,431,000 kg CO2e. The Scope 3 emissions for that year were 382,000 kg CO2e. Hutchmed's emissions increased from approximately 7,551,000 kg CO2e in 2021, where Scope 1 emissions were 313,000 kg CO2e and Scope 2 emissions reached 7,900,000 kg CO2e, to the 2023 figures. The company has not disclosed any specific reduction targets or initiatives, indicating a lack of formal commitments to reduce emissions at this time. Overall, Hutchmed's emissions data reflects a growing trend in total emissions, particularly in Scope 3, which highlights the importance of addressing supply chain and operational impacts in their climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 14,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 5,073,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 262,000 | 000,000 | 000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hutchmed is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
